FGP
AUPH icon

Freestone Grove Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Freestone Grove Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.3M Buy
87,989
+74,367
+546% +$1.09M 0.01% 428
2025
Q4 		$217K Buy
+13,622
New +$193K ﹤0.01% 692

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Freestone Grove Partners's AUPH Position: Q1 2026 in Review

Freestone Grove Partners increased its Aurinia Pharmaceuticals (AUPH) stake by 546% in Q1 2026, buying an estimated $1.09M and bringing the position to 87,989 shares worth $1.3M. The position accounts for 0.01% of the portfolio, ranked #428.

Freestone Grove Partners first reported a position in AUPH in Q4 2025 and has held it in 2 quarters since. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Freestone Grove Partners held 87,989 shares of Aurinia Pharmaceuticals worth $1.3M as of Q1 2026.
  • Freestone Grove Partners bought 74,367 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $1.09M.
  • Aurinia Pharmaceuticals made up 0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #428 holding.
  • Freestone Grove Partners first reported a position in Aurinia Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.